Compare PBH & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | ZYME |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2004 | 2022 |
| Metric | PBH | ZYME |
|---|---|---|
| Price | $45.10 | $25.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $67.80 | $41.23 |
| AVG Volume (30 Days) | 451.4K | ★ 494.2K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $975,777,000.00 | $105,965,000.00 |
| Revenue This Year | $17.03 | $186.92 |
| Revenue Next Year | $6.06 | $16.24 |
| P/E Ratio | $76.54 | ★ N/A |
| Revenue Growth | 36.77 | ★ 38.87 |
| 52 Week Low | $42.62 | $16.00 |
| 52 Week High | $71.07 | $31.34 |
| Indicator | PBH | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 47.17 |
| Support Level | $44.73 | $22.10 |
| Resistance Level | $49.79 | $27.30 |
| Average True Range (ATR) | 1.30 | 1.09 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 32.07 | 33.08 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.